 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 143
Date: January 6, 2024
Two guys walk into an oncologist’s office. Both have CLL, both decide that RF (Rituxan + fludarabine) therapy is the way to go. Both get a “CR” — a complete response. So far so good.
Here is where it gets interesting. Since both of our guys got the same response at the end of the RF therapy, namely a CR, do you think they are likely to be in remission for the same length of time, and even more important, they will stay alive for the same length of time? A rose by any name smells as sweet, but does a CR give all patients the same benefit?
The answer might surprise you. The latest paper out of Ohio State University says crucial statistics such as “progression free survival” and “overall survival” are partly baked into the cake even before the patient gets the first shot of RF therapy.
This is a must read paper if you are considering RF therapy now or in the future. You can read our review of it on RF Risks and Benefits.
Be well,
Chaya
____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
